Overview of novel routes of insulin: current status


  • Lopamudra Roy Department of Pharmacology, Apeejay Stya University, Haryana, India
  • Mounamukhar Bhattacharjee Department of Pediatrics, AIIMS, Jodhpur, Rajasthan, India




Glycemic control, Mellitus, Drug administration routes, Inhalation insulin


Diabetes mellitus is the chronic pathogenic condition which is primarily due to inadequate insulin secretion and is responsible for major healthcare problems worldwide cost billions of dollars annually. For more than 84 years of time, Insulin replacement therapy had been used to manage to overcome the complications and this present review is based on the various routes of insulin delivery based on its safety and efficacy. Depending upon the effective duration of action, insulin activity varies from 1.5 to 27 hours and to reduce insulin burden, now a days it can be delivered in sensor-augmented pump therapy, various types of insulin Pen as well as routes like inhalation, colonic insulin, buccal, intra- peritonea and ocular, rectal, vaginal delivery of insulin etc. had been added to it. This review examines some of the recent proposals for various routes of application of Insulin delivery system along with the particular attention to its latest intervention of novel drug delivery system.


Tabakha AI, Arida AI. Recent challenges in insulin delivery systems: A review. Indian J. Pharm Sci. 2008;70:278-86.

Varshney HM, Rajnish K, Shailender M. Novel Approaches for Insulin Delivery: Current Status. International J Therap Applic. 2012;7:25-31.

Diabetes - Fact Sheet No. 312: World Health Organization; 2013. Available at: https://www.endo.theclinics.com/article/S0889-8529(13)00037-6/abstract#back-bib1. Accessed on 25 June 2013.

Chen MC, Sonaje K, Chen KJ, Sung HW. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011;32:9826-38.

Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther. 2004;6:510-17.

Bargman JM. Intraperitoneal versus subcutaneous insulin in patients on nighttime IPD.Adv Perit Dial. 1994;10:116-9.

Chin RL, Martinez R, Garmel G. Gas gangrene from subcutaneous insulin administration. Am J Emerg Med. 1993;11:622-5.

Gemmil CL. The Greek concept of diabetes. Bull N Y Acad Med. 1972;48:1033-6.

Bliss M. The history of insulin. Diabetes Care. 1993;16(3):4-7.

Uianzon CC, Cheikh I. History of Insulin. J Commu Hospital Internal Med Pers 2012;2(2):1-3.

Joshi SR, Parikh RM, Das AK. Insulin History, Biochemistry, Physiology and Pharmacology. Supplement Japi. 2007;55:19-25.

Shashank RJ, Rakesh MP, Das AK. Insulin History, Biochemistry, Physiology and Pharmacology. Supplement Japi.2007;55:19-25.

Bell GI, Picket RL, Rutter WJ. Sequence of the human insulin gene. Nature. 1980;284:26-32.

Bliss M. The discovery of Insulin, Chicago: University of Chicago. Press, 1982.

Eckardt K, Eckel J.Insulin analogues: action profiles beyond glycaemic control. Arch Physiol Biochem. 2008;114(1):45-153.

Becker RHA. Insulin glulisine complementing basal insulin: a review of structure and activity. Diabetes Technol Therap.2007;9(1):109-21.

Garnock-Jones KP, Plosker GL. Insulin glulisine: a review of its use in the management of diabetes mellitus. 2009;69(8):1035-57.

Hagenmeyer EG, Schadlich PK, Koster AD, Dippel FW, Haussler B. Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues. Deutsche Medizinische Wochenschrift. 2009;134(12):565-70.

Elrishi MA, Jarvis J, Khunti K, Davies MJ. Insulin glargine and its role in glycaemic management of Type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology. 2008;4(8):1099-110.

Chapman TM, Noble S, Goa K. Spotlight on insulin aspart in type 1 and 2 diabetes mellitus. Treat Endocrino. 2003;2(1):71-6.

Vasiliki V. Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin pumps. J Diabetes Res. 2010;1-14.

Hagenmeyer EG, Schadlich PK, Koster AD, Dippel FW, Haussler B. Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues. Deutsche Medizinische Wochenschrift. 2009;134(12):565-70.

Morales J. Defining the role of insulin detemir in basal insulin therapy. Drugs. 2007;67(17):2557-84.

Jacob S, Morsy MA, Nair A. A Overview on the Insulin Preparations and Devices. Indian J Pharmac Edu Res. 2018;52(4): 550-57.

Greenway SE, Filler LE, Greenway FL. Topical insulin in wound healing: a randomised, double-blind, placebo-controlled trial. J Wound Care. 1999;8:526-8.

Zhang XJ, Wu X, Wolf SE, Hawkins HK, Chinkes DL, Wolfe RR. Local insulin-zinc injection accelerates skin donor site wound healing. J Surg Res. 2007;142:90-6.

Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G. Special report: safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004;28:39-70.

Scheen AJ. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? Diabetes Metab. 2005;31(1):27-34.

Donati A, Cavallini G, Carresi C, Gori Z, Parentini I, Bergamini E. Anti-aging effects of anti-lipolytic drugs. Exp Gerontol. 2004;39:1061-67.

Hayashi I, Larner J, Sato G. Hormonal growth control of cells in culture. Cell Dev Biol. 1978;14:23-30.

Guiberta EE, Petrenkob AY, Balabana CL, Somovb AY, Rodrigueza JV, Fullerc BJ. Organ preservation: current concepts and new strategies for the next decade. Transfus Med Hemother. 2011;38:125-42.

Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005;365:63-78.

Das UN. Critical advances in septicemia and septic shock. Crit Care. 2000;4:290-4.

McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin. 2001;17:107-24.

Fry A. Insulin delivery device technology 2012: Where are we after 90 years? J Diabetes Sci Technol. 2012;6:947-53.

Selam JL. Evolution of diabetes insulin delivery devices. J diabetes Sci Technol. 2010;4:505-13.

Saboo BD, Talaviya PA. Continuous Subcutaneous Insulin Infusion: practical issues. Indian J Endocrinol Metabol. 2012;259-62.

Neville KA, Ross LJ. Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections for Type 1 Diabetes. J Paedia and Child Health. 2019;55(6):718-22.

Brazg RL, Bailey TS, Garg S, Buckingham BA, Slover RH, Klonoff DC. The ASPIRE study: Design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol. 2011;5:1466-71.

Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH et al. Threshold- Based Insulin-pump Interruption for Reduction of Hypoglycemia. New Eng J Med. 2013;369:224-32.

Brashier DBS, Khadka A, Anantharamu T, Sharma AK, Gupta AK, Sharma S, Dahiya NK. Inhaled Insulin: A puff than a shot before meals. J Pharmacol Pharmacotherap. 2015;6:126-129.

Gowtham T, Rafi K, Gopi CK, Nagasaraswati M. Facts on inhaled insulin. J App Pharmacea Sci. 2011;18-23.

Mohanty RR, Das S. Inhaled Insulin Current Direction of Insulin Research. J Clin Diagnostic Res. 2017:01-02.

Fonte P, Araujo F, Reis S, Sarmento B. Oral Insulin Delivery: How Far Are We? J Diabetes Sci Technol. 2013;7:520-31.

Aminabhavi TM. Oral Insulin Therapy for Diabetic Treatment. J Pharmace care Health. 2014;1(4):1-2.

Arbit E, Kidron M. Oral Insulin Delivery in a Physiologic Context: Review. J Diabetes Sci Technol. 2017;11(4):825-32.

Nicholas ME, Panaganti S, Prabakaran L, Jayveera KN. Novel Colon Specific Drug Delivery System: A Review. Int J Pharmace Sci Res. 2011;2(10):2545-61.

Rahman SK, Kawatra P. Insulin delivery: what is new in the queue? Int J Basic Clin Pharmacol. 2016;6:229-33.

Illum L. Nasal drug delivery Recent developments and future prospects. J Controll Release. 2012;161(2):254-63.

Shah RB, Patel M, Maahs DM, Shah VN. Insulin delivery methods: Past, Present and Future. Int J Pharmace Investi. 2016;6(1):1-9.

Lee YC, Yalkowsky SH, Pahala S, Pinsuwan S. Review on the systemic delivery of insulin via the ocular route. Int J Pharmacueu. 2002;233:1-18.

Bartlett JD, Henson AT, Atchison JA, Woolley TW, Pillion DJ. Insulin Administration to the Eyes of Normoglycemic Human Volunteers. J ocular pharmacol and therapeutics. 2009;10(4):15-21.

Shichiri M. Increase intestinal absorption of insulin: an insulin suppository J Pharmacy Pharmacol. 1978;30(12):806-8.

Sindhu A, Bharath S, Furtado S, Deveswaran R, Basavaraj BV. Development and advances in insulin delivery. S Afr Pharm J. 2011;78(6):32-7.

Bargman JM. Intraperitoneal versus subcutaneous insulin in patients on nighttime IPD. Adv Perit Dial. 1994;10: 116-9.

Kumria R, Goomber G. Emerging trends in insulin delivery. J Diabetol. 2011;2(2):5-10.

Ching L, Gupta M. Transdermal drug delivery systems in diabetes management: A review. Asian J Pharmaceutical Scie. 2020;15:13-25.

Darvishha S, Amiri S. (Trans)dermal insulin delivery based on polymeric systems. Int J Polymeric Materials Polymeric Biomaterials. 2019;68(18):1118-32.

Hultstrom M, Roxhed N, Nordquist L. Intradermal Insulin Delivery: A Promising Future for Diabetes Management. J Diabetes Sci Technol. 2014;8(3):453-7.

Schade DS, Eaton PR, Fruedman NM, Spencer WJ. five - Day programmed Intraperitoneal Insulin Delivery in Insulin Dependent Diabetic Man’; The Journal of Clinical Endocrinology and Metabolism. 1981;52(6):1165-70.

Dijk PRV, Logtenber SJJ, Chisalita SI, Hedman CA, Groenier KH, Gans ROB et al. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGH-1 Axis in Type 1 Diabetes. J Clin Endocrinol Metabol. 2016;101(6):2493-501.

Desai TA, West T, Cohen M, Boiarski T, Rampersaud A. Nanoporous microsystems for islet cell replacement. Adv Drug Deliv Rev. 2004;56:1661-73.

Sekigami T, Shimoda S, Nishida K, Matsuo Y, Ichimori S, Ichinose K. Comparison between closed-loop portal and peripheral venous insulin delivery systems for an artificial endocrine pancreas. J Artif Organs. 2004;7:91-100.

Green A, Christian HN, Pramming SK. The changing world demography of type 2 diabetes. Diabetes Metab Res Rev. 2003;19:3-7.

Yadav S, Parakh A. Insulin Therapy. Indian Pediatr. 2006;43(10):863-72.






Review Articles